Dr Syd Johnson | Vice President of Antibody Engineering

Dr Syd Johnson, Vice President of Antibody Engineering, Macrogenics

Syd Johnson, Ph.D., V.P. of Antibody Engineering at MacroGenics, Inc., has over twenty-five years of experience in the antibody engineering field.  Prior to joining MacroGenics in 2001, he spent eleven years at MedImmune, Inc., where he led the preclinical efforts to develop humanized monoclonal antibodies.  Dr. Johnson is the inventor of Synagis, MedImmune’s anti-RSV product, which is still the only licensed monoclonal antibody product for prevention of viral infection.  Prior to that, he worked for six years at Genex Corporation, during which time he was involved in pioneering work in the development of scFv technology.  In addition to a long list of scientific publications, Dr. Johnson is an inventor on over 50 issued United States patents.


EAC 2017 Day 2, Wednesday 1st November 2017 @ 12:25

Novel DART and TRIDENT molecules with unique modes of action

  • Advancing half-life extended DART molecules for redirected T-cell killing
  • Strategies to target checkpoint and costimulatory pathways
  • Adapting TRIDENT protein’s avidity and valency to address diverse modes of action

back to speakers